AKRO Akero Corp: Rasio rega marang prakiraan pendapatan

Akero Therapeutics - logo grafis emiten AKRO

Akero Therapeutics (AKRO) aims to commercialize innovative treatments for steatohepatitis while remaining in the clinical trial stage. The strategy relies on close collaboration with hepatologists to establish proprietary standards of care. The expert team is actively expanding through stock options and the recruitment of specialized professionals. The forward P/S history helps assess the market value of future sales, while shows the current value of the metric.

Akero - Rasio kapitalisasi marang dodolan sing dikarepake AKRO (periode 04.07.2022 - 15.11.2026)

Ringkesan rincian data analitis Akero Therapeutics (AKRO)

- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
Analisis fundamental perusahaan:AKRO (Akero Therapeutics, Inc.)
Produk asli Akero Corp

Akero Therapeutics (AKRO) is developing targeted MASH therapy, where the business valuation is based on the commercialization potential of efruxifermin and its attractiveness for M&A. The company's forward P/S reflects a market premium over expected sales, measuring investors' willingness to pay a premium for future revenue growth; an analysis of the company's forward P/S allows for the identification of asset overvaluation risks should the drug's development pace slow.

Pesaing Akero Therapeutics

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|MTSR: Multiplikator Forward P/S|MLTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan soleno.life (SLNO)|Multiplikator forward rega marang pendapatan Amicus Therapeutics FOLD|Rega forward marang dodolan 89bio Inc|Multiplikator Forward P/S Agios Pharmaceuticals, Inc. AGIO|GPCR: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake MiMedx Corp MDXG|RZLT (Rezolute Corp) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan LXRX|MBX (MBX Biosciences) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Altimmune Inc (ALT)|Multiplikator forward rega marang pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator forward rega marang pendapatan Sagimet SGMT|Multiplikator Forward P/S BIOA (BioAge Labs)|Multiplikator Forward P/S Biomea Fusion BMEA|QNCX: Multiplikator forward rega marang pendapatan|GUTS: Rasio rega marang prakiraan pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC: Rasio rega marang pendapatan sing dikarepake|PLUR (pluri-biotech.com) - Multiplikator Forward P/S|SYBX: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake Matinas BioPharma Holdings, Inc.|Rasio rega marang prakiraan pendapatan Spruce Biosciences Inc. SPRB|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|LUMO - Multiplikator Forward P/S|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan